OBJECTIVE： To investigate the clinical efficacy and safety of Cinobufacin capsules combined with radiotherapy in the treatment of median and advanced nasopharyngeal carcinoma. METHODS： Ninety-five patients with median and advanced nasopharyngeal carcinoma in cancer center of our hospital during 2011-2012 were analyzed retrospectively， and then divided into control group （57 cases） and observation group （38 cases） according to therapy plan. Control group received radiotherapy alone， while observation group was additionally given Cinobufacin capsule 0.5 g， tid， till the end of radiotherapy. A treatment course lasted for 4 weeks. The prolonged radiotherapy were compared between 2 groups. Clinical response rate was observed in 2 group， and 1-year and 3-year survival rate and the occurrence of ADR were followed up. RESULTS： The proportion of prolonged radiotherapy was 89.47％ in control group， which was significantly higher than 52.63％ of observation group， with statistical significance （P＜0.05）. At the end of therapy and one month after therapy， clinical total response rates of observation group were 81.58％ and 63.16％， which were significantly higher than 70.18％ and 45.61％ of control group， with statistical significance （P＜0.05）. The incidence of white blood cell lowering， hemoglobin lowering， local side effect of radiotherapy，  nasopharyngeal dysphagia/odynophagia in observation group were significantly lower than in control group， with statistical significance （P＜0.05）. There was no statistical significance in survival rate between 2 groups in 1st-year and 3rd-year follow-up （P＞0.05）. CONCLUSIONS： Cinobufacin capsule combined with radiotherapy can significantly relieve the side effects of radiotherapy in median and advanced nasopharyngeal carcinoma patients.